We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Read MoreHide Full Article
Key Takeaways
Novo's denecimig FDA review is extended as manufacturing facility remediation work continues.
The FDA cited facility issues, not clinical efficacy or safety data, as the reason for the delay.
Novo still targets a U.S. launch for denecimig in the first half of 2027, pending approval.
Novo’s (NVO - Free Report) denecimig biologics license application (BLA) review in the United States is facing an extended timeline after the FDA informed the company that the review of the investigational therapy for haemophilia A remains ongoing. The FDA has not provided a new date for regulatory action, with facility remediation activities cited as the reason for the extension. Novo said the agency has not identified any deficiencies related to the clinical efficacy or safety data included in the application.
Novo’s denecimig is an investigational FVIIIa-mimetic bispecific antibody being developed as a subcutaneous prophylactic treatment for adults and children with haemophilia A, including patients with inhibitors. The therapy’s unique mechanism of action helps restore thrombin generation and support blood clot formation. Novo is developing the candidate for once-monthly, every-two-weeks and weekly dosing.
NVO’s Denecimig BLA Review Faces Delay From Facility Remediation
Novo submitted the denecimig BLA to the FDA in September 2025 seeking approval for adult and pediatric patients with haemophilia A. At the time of filing, the company anticipated a regulatory decision in the third quarter of 2026. Following the submission, the FDA conducted a pre-license inspection of the manufacturing facility and subsequently provided feedback that led to remediation requirements. The latest update indicates that the manufacturing facility, rather than concerns over denecimig’s clinical profile, is driving the extended review. Novo is continuing to implement corrective measures and is working with the FDA to address the outstanding manufacturing requirements.
Year to date, NVO shares have lost 26.6% against the industry’s 9.5% growth.
Image Source: Zacks Investment Research
Importantly, the FDA has not identified deficiencies related to denecimig’s clinical efficacy or safety data. This keeps the current regulatory delay centered on manufacturing rather than the benefit-risk profile demonstrated in the clinical development program. Per Novo, the feedback concerning the manufacturing site does not affect its other marketed products. The company expects the additional review time to have no impact on its 2026 financial outlook, helping contain the near-term business implications of the delayed U.S. decision. Pending the regulatory decision, the company continues to target a U.S. launch of denecimig in the first half of 2027.
The U.S. BLA submission for denecimig was supported by clinical data from the FRONTIER development program, including pivotal phase III FRONTIER2 and FRONTIER3 studies, which evaluated denecimig in adults, adolescents and children with haemophilia A, with or without inhibitors. FRONTIER2 assessed monthly and weekly dosing in adults and adolescents aged 12 years and older, while FRONTIER3 evaluated the same regimens in children younger than 12. FRONTIER4 is an open-label extension study evaluating every-two-weeks dosing and the long-term safety of denecimig across monthly, every-two-weeks and weekly regimens.
In the EU, denecimig reached an important regulatory milestone after receiving a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) last month, recommending its approval. A final decision from the European Commission (EC) on the marketing authorization application is still pending, while the candidate is also under review by other regulatory authorities. Though not legally binding, the CHMP opinion will be considered by the EC in its final decision on the marketing authorization. The positive opinion marks an important regulatory milestone for denecimig and strengthens Novo’s prospects of advancing the therapy toward commercialization in Europe and other markets.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have increased 104.3% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 13.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 77.4% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Shutterstock
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
Key Takeaways
Novo’s (NVO - Free Report) denecimig biologics license application (BLA) review in the United States is facing an extended timeline after the FDA informed the company that the review of the investigational therapy for haemophilia A remains ongoing. The FDA has not provided a new date for regulatory action, with facility remediation activities cited as the reason for the extension. Novo said the agency has not identified any deficiencies related to the clinical efficacy or safety data included in the application.
Novo’s denecimig is an investigational FVIIIa-mimetic bispecific antibody being developed as a subcutaneous prophylactic treatment for adults and children with haemophilia A, including patients with inhibitors. The therapy’s unique mechanism of action helps restore thrombin generation and support blood clot formation. Novo is developing the candidate for once-monthly, every-two-weeks and weekly dosing.
NVO’s Denecimig BLA Review Faces Delay From Facility Remediation
Novo submitted the denecimig BLA to the FDA in September 2025 seeking approval for adult and pediatric patients with haemophilia A. At the time of filing, the company anticipated a regulatory decision in the third quarter of 2026. Following the submission, the FDA conducted a pre-license inspection of the manufacturing facility and subsequently provided feedback that led to remediation requirements. The latest update indicates that the manufacturing facility, rather than concerns over denecimig’s clinical profile, is driving the extended review. Novo is continuing to implement corrective measures and is working with the FDA to address the outstanding manufacturing requirements.
Year to date, NVO shares have lost 26.6% against the industry’s 9.5% growth.
Image Source: Zacks Investment Research
Importantly, the FDA has not identified deficiencies related to denecimig’s clinical efficacy or safety data. This keeps the current regulatory delay centered on manufacturing rather than the benefit-risk profile demonstrated in the clinical development program. Per Novo, the feedback concerning the manufacturing site does not affect its other marketed products. The company expects the additional review time to have no impact on its 2026 financial outlook, helping contain the near-term business implications of the delayed U.S. decision. Pending the regulatory decision, the company continues to target a U.S. launch of denecimig in the first half of 2027.
The U.S. BLA submission for denecimig was supported by clinical data from the FRONTIER development program, including pivotal phase III FRONTIER2 and FRONTIER3 studies, which evaluated denecimig in adults, adolescents and children with haemophilia A, with or without inhibitors. FRONTIER2 assessed monthly and weekly dosing in adults and adolescents aged 12 years and older, while FRONTIER3 evaluated the same regimens in children younger than 12. FRONTIER4 is an open-label extension study evaluating every-two-weeks dosing and the long-term safety of denecimig across monthly, every-two-weeks and weekly regimens.
In the EU, denecimig reached an important regulatory milestone after receiving a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) last month, recommending its approval. A final decision from the European Commission (EC) on the marketing authorization application is still pending, while the candidate is also under review by other regulatory authorities. Though not legally binding, the CHMP opinion will be considered by the EC in its final decision on the marketing authorization. The positive opinion marks an important regulatory milestone for denecimig and strengthens Novo’s prospects of advancing the therapy toward commercialization in Europe and other markets.
Novo Nordisk A/S Price and Consensus
Novo Nordisk A/S price-consensus-chart | Novo Nordisk A/S Quote
NVO's Zacks Rank & Stocks to Consider
Novo currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents to earnings per share of 24 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 73 cents. PGEN shares have increased 104.3% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 13.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 77.4% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.